viewWhole Foods Market Inc

Whole Foods Market reports higher profit in Q3


Whole Foods Market (NASDAQ:WFM) modestly boosted its outlook for fiscal 2013 after it said net income rose 21 per cent in the third quarter.

The organic food supermarket chain firmed up its full fiscal year sales guidance to 11 per cent, compared to the previous 10 to 11 per cent range, and set a three to four per cent outlook for the fourth quarter. The full-year forecast falls short of the 11.4 per cent predicted by the street. The fourth quarter guidance also falls short of the 5.2 per cent street estimate.

Same-store sales are expected to rise between 7.2 to 7.3 per cent for the fiscal year, a tighter range than the 6.7 to 7.5 per cent prior estimate.

The company expects earnings per share in a $1.45 to $1.46 per share range, revised from$1.43 to $1.45 per share. The analyst consensus is for $1.45 per share. 

For the third quarter, sales increased 12 per cent to $3.1 billion, in line with analyst forecasts. Same-store sales rose 7.5 per cent, while net income spiked 21 per cent to $142 million or 38 cents per share from $117 million or 31 cents per share. 

Whole Foods has a 1,000-store target "over the long term," nearly triple the number of stores it has now. The company will open 32 stores this year and between 33 to 38 next year. 

Shares fell 1.6 per cent after hours on Wednesday.

Quick facts: Whole Foods Market Inc


Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress. The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate,...

7 hours, 31 minutes ago

2 min read